Skip to main content

Table 5 Adverse drug reactions occurring in ≥3% of patients

From: Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study

 

<65 years

(n = 146)

≥65 years

(n = 108)

ALL

(N = 254)

All grade

Grade ≥3

All grade

Grade ≥3

All grade

Grade ≥3

Any

120 (82.2)

103 (70.5)

92 (85.2)

76 (70.4)

212 (83.5)

179 (70.5)

Hematological toxicity

 Neutropenia

82 (56.2)

73 (50.0)

72 (66.7)

64 (59.3)

154 (60.6)

137 (53.9)

 Leukopenia

84 (57.5)

67 (45.9)

66 (61.1)

54 (50.0)

150 (59.1)

121 (47.6)

 Lymphopenia

26 (17.8)

24 (16.4)

14 (13.0)

14 (13.0)

40 (15.7)

38 (15.0)

 Anemia

14 (9.6)

10 (6.8)

16 (14.8)

10 (9.3)

30 (11.8)

20 (7.9)

 Thrombocytopenia

7 (4.8)

4 (2.7)

2 (1.9)

1 (0.9)

9 (3.5)

5 (2.0)

 Febrile neutropenia

3 (2.1)

3 (2.1)

6 (5.6)

6 (5.6)

9 (3.5)

9 (3.5)

Non-hematological toxicity

 Peripheral neuropathy

18 (12.3)

2 (1.4)

12 (11.1)

3 (2.8)

30 (11.8)

5 (2.0)

 Stomatitis

5 (3.4)

0

4 (3.7)

1 (1.0)

9 (3.5)

1 (0.4)

 Alopeciaa

7 (4.8)

–

4 (3.7)

–

11 (4.3)

–

 Malaise

8 (5.5)

1 (0.7)

5 (4.6)

0

13 (5.1)

1 (0.4)

 Pyrexia

7 (4.8)

0

2 (1.9)

0

9 (3.5)

0

Laboratory test abnormalities

 ALT-increased

23 (15.8)

3 (2.1)

10 (9.3)

0

33 (13.0)

3 (1.2)

 AST-increased

20 (13.7)

2 (1.4)

12 (11.1)

0

32 (12.6)

2 (0.8)

 γ-GTP increased

11 (7.5)

8 (5.5)

2 (1.9)

1 (0.9)

13 (5.1)

9 (3.5)

 CRP increased

8 (5.5)

2 (1.4)

9 (8.3)

5 (4.6)

17 (6.7)

7 (2.8)

 Hemoglobin decreased

10 (6.8)

4 (2.7)

2 (1.9)

2 (1.9)

12 (4.7)

6 (2.4)

  1. Data are presented as n (%). ALT alanine aminotransferase, AST aspartate aminotransferase, CRP C-reactive protein, GTP glutamyl transferase
  2. a Grading for alopecia is not available as indicated by ‘-‘